Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06532734 · ClinicalTrials.gov registry record
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
A clinical trial of Esophageal Adenocarcinoma and Eating Disorders, sponsored by Denver Health and Hospital Authority.
- Recruiting
- Registry status
- 25
- Enrollment target
- 3
- Study locations
NCT06532734 is a study of Esophageal Adenocarcinoma and Eating Disorders that is actively recruiting participants, run by Denver Health and Hospital Authority. The registered enrollment target is 25 participants, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT06532734, a study of Esophageal Adenocarcinoma and Eating Disorders, is actively recruiting participants, sponsored by Denver Health and Hospital Authority.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors
Conditions Studied
Interventions
- DEVICE EsoGuard
Study Locations (3)
Colorado
- ACUTE Center for Eating Disorders and Severe Malnutrition - Denver
- Denver Health and Hospital Authority - Denver
- Denver Health and Hospital Authority - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2026-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06532734
The ClinicalTrials.gov registry entry for NCT06532734 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (92% lower). The listed sponsor is Denver Health and Hospital Authority, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which EsoGuard is the first listed.
NCT06532734 reports 3 study locations spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06532734 about?
NCT06532734 is a clinical study titled "Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype". To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors
What is the current status of trial NCT06532734?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2024-11-12. Estimated completion is 2026-11.
What conditions does trial NCT06532734 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Eating Disorders, Barrett Esophagus, Vomiting, Rumination.
What interventions are being tested in trial NCT06532734?
The interventions under investigation include: EsoGuard (DEVICE).
Who is sponsoring clinical trial NCT06532734?
This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06532734 being conducted?
This trial has 3 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.